Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monastrol is a cell-permeable small molecule that acts as a reversible and selective inhibitor of the mitotic kinesin Eg5 (also known as KIF11 or kinesin‑5), a motor protein essential for spindle bipolarity during mitosis. By binding to an allosteric site unique to Eg5 family members and inhibiting its ATPase activity, monastrol disrupts proper spindle formation and arrests cells in mitosis without interacting with tubulin. It was discovered by Thomas U. Mayer in Tim Mitchison’s lab and has been widely used as a research tool to probe mechanisms of cell division[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monastrol.